Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

被引：0

作者：

Bissonnette, R. ^{[1
]}

Iversen, L. ^{[2
]}

Sofen, H. ^{[3
]}

Griffiths, C. E. M. ^{[4
,5
]}

Foley, P. ^{[6
]}

Romiti, R. ^{[7
]}

Bachinsky, M. ^{[8
]}

Rottinghaus, S. T. ^{[8
]}

Tan, H. ^{[8
]}

Proulx, J. ^{[8
]}

Valdez, H. ^{[9
]}

Gupta, P. ^{[8
]}

Mallbris, L. ^{[10
]}

Wolk, R. ^{[8
]}

机构：

[1] Innovaderm Res, Montreal, PQ, Canada

[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[3] Univ Calif Los Angeles, Sch Med, Dept Med Dermatol, Los Angeles, CA USA

[4] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England

[5] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[6] Univ Melbourne, Skin & Canc Fdn Inc, Carlton, Vic 3053, Australia

[7] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil

[8] Pfizer Inc, Groton, CT 06340 USA

[9] Pfizer Inc, New York, NY USA

[10] Pfizer Inc, Collegeville, PA USA

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2015年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：37 / 37

页数：1

共 50 条

[21] Apremilast in moderate-to-severe plaque psoriasis (ESTEEM 2 trial)
Anstey, Alex
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : E23 - E23
[22] Risankizumab in moderate-to-severe plaque psoriasis
Serrano, Linda
Maloney, Victoria
Gordon, Kenneth B.
IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
[23] Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
Heydendael, VMR
Spuls, PI
Opmeer, BC
de Borgie, CAJM
Reitsma, JB
Goldschmidt, WFM
Bossuyt, PMM
Bos, JD
de Rie, MA
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 658 - 665
[24] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
la Rosa, Carmen
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226
[25] Treatment of moderate-to-severe plaque psoriasis
Salgo, R.
Thaci, D.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
[26] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Kory P. Schrom
Avi Bitterman
Neil J. Korman
Current Dermatology Reports, 2019, 8 : 6 - 13
[27] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Schrom, Kory P.
Bitterman, Avi
Korman, Neil J.
CURRENT DERMATOLOGY REPORTS, 2019, 8 (01) : 6 - 13
[28] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
Scanlon, James V.
Exter, Benjamin P.
Steinberg, Michael
Jarvis, Courtney I.
ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
[29] The transition from mild to moderate-to-severe chronic plaque psoriasis
Bellinato, Francesco
Gisondi, Paolo
Mioso, Guido
Mason, Elena
Straiotto, Danny
Piaserico, Stefano
Girolomoni, Giampiero
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : E1215 - E1217
[30] Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial
Papp, KA
Bressinck, R
Fretzin, S
Goffe, B
Kempers, S
Gordon, KB
Caro, I
Walicke, PA
Wang, XL
Menter, A
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (05) : 605 - 614

← 1 2 3 4 5 →